Patents for A61P 35 - Antineoplastic agents (221,099)
01/2010
01/26/2010US7652042 Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments
01/26/2010US7652036 Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
01/26/2010US7652031 Compounds which mimic the chemical and biological properties of discodermolide
01/26/2010US7652022 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea;
01/26/2010US7651999 2′, 5′-oligoadenylate analogs
01/26/2010US7651998 administering a Venezuelan Equine Encephalitis (VEE) vector (alpha virus vector) comprising a heterologus nucleotide sequence to a subject; concurrently administering an antibody that specifically binds to the E1 and/or the E2 glycoprotein of the VEE vector to produce immune response to cancer patient
01/26/2010US7651997 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them
01/26/2010US7651857 Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling
01/26/2010US7651698 Prolonged release bioadhesive therapeutic systems
01/26/2010US7651678 Methods to impair hematologic cancer progenitor cells and compounds related thereto
01/26/2010CA2642066C Immuno-interactive fragments of the .alpha.c subunit of inhibin
01/26/2010CA2555345C Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
01/26/2010CA2499354C Transcription control factor zhx3
01/26/2010CA2481012C Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
01/26/2010CA2470064C Triazolo-quinolin derivatives useful as adenosine receptor ligands
01/26/2010CA2469380C Heteroaryl-substituted aminocyclohexane derivatives
01/26/2010CA2465206C Polymeric thiol-linked prodrugs
01/26/2010CA2456606C 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
01/26/2010CA2434731C Modular infusion device and method
01/26/2010CA2421588C Tnf receptor-like molecules and uses thereof
01/26/2010CA2408710C Compositions and methods for the treatment of colorectal cancer
01/26/2010CA2393083C Use of hypoglycemic agent for treating impaired glucose metabolism
01/26/2010CA2390263C Method for producing metabolites from plants cultivated in soil-less medium
01/26/2010CA2350031C N-arylsulfonylamino acid omega-amides
01/26/2010CA2349629C Methods for the production of tcr gamma delta t cells
01/26/2010CA2328803C Anti-procalcitonin antibodies and the preparation and use thereof
01/26/2010CA2303934C Tetrazole-containing rapamycin analogs with shortened half-lives
01/26/2010CA2301499C T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof
01/26/2010CA2275345C Pro-drugs and counterparts of camptothecin, their application as medicines
01/26/2010CA2230086C Method to improve the biological and antiviral activity of protease inhibitors
01/26/2010CA2222524C Somatostatin peptides
01/26/2010CA2204666C Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
01/21/2010WO2010009342A2 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
01/21/2010WO2010009285A1 Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
01/21/2010WO2010009280A1 Use of hdac inhibitors for the treatment of hodgkin's disease
01/21/2010WO2010009183A1 Pyridone and pyridazone analogues as gpr119 modulators
01/21/2010WO2010009155A2 Fused heterocyclyc inhibitor compounds
01/21/2010WO2010009124A2 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
01/21/2010WO2010008876A2 Method for preparation of micellar hybrid nanoparticles for therapeutic and diagnostic applications and compositions thereof
01/21/2010WO2010008852A2 Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
01/21/2010WO2010008843A1 Apoptosis signal-regulating kinase 1 inhibitors
01/21/2010WO2010008744A2 Antineoplastic combinations containing hki-272 and vinorelbine
01/21/2010WO2010008619A2 Extended release pharmaceutical formulations of s-adenosylmethionine
01/21/2010WO2010008558A1 Compounds and methods of inducing apoptosis via interaction with chaperonin cct
01/21/2010WO2010008554A2 Methods and products for treating proliferative diseases
01/21/2010WO2010008528A2 Marek's disease virus vaccine compositions and methods of using thereof
01/21/2010WO2010008454A1 Protein kinase inhibitors
01/21/2010WO2010008263A1 Use of thalidomide to inhibit the osteoclast-activation process associated with multiple myeloma disease
01/21/2010WO2010008075A1 Anti-system asc amino acid transporter 2 (asct2) antibody
01/21/2010WO2010008069A1 Cell proliferation inhibitor
01/21/2010WO2010008051A1 Anti-human clcp1 antibody and use thereof
01/21/2010WO2010008001A1 Aptamer against il-17 and use thereof
01/21/2010WO2010007972A1 Novel indole derivative having carbamoyl group, ureide group and substituted oxy group
01/21/2010WO2010007800A1 Novel uracil compound having amide structure and salt thereof
01/21/2010WO2010007756A1 Pyridine derivative having ttk inhibition activity
01/21/2010WO2010007724A1 Peptide capable of binding to epcam
01/21/2010WO2010007531A2 Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering from chronic myeloid leukaemia
01/21/2010WO2010007464A1 USE OF DEFENSIN α1 AND/OR DEFENSIN α4, AS A MARKER FOR PREDICTING A RELAPSE IN A PATIENT SUFFERING FROM CHRONIC MYELOID LEUKAEMIA
01/21/2010WO2010007427A1 Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases
01/21/2010WO2010007389A1 5 -amidothiazole derivatives and their use as checkpoint kinase inhibitors
01/21/2010WO2010007374A1 Pharmaceutical compounds
01/21/2010WO2010007318A2 Novel imidazo[1,2-a]pyrimidine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors
01/21/2010WO2010007317A1 Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as met inhibitors
01/21/2010WO2010007316A2 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors
01/21/2010WO2010007252A2 Formulation for improving the bioavailability of a hydrophobic molecule
01/21/2010WO2010007248A2 Novel tricyclic derivatives, process for the preparation thereof and pharmaceutical compositions containing same
01/21/2010WO2010007169A1 Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases
01/21/2010WO2010007120A1 Pyridazine derivatives as smo inhibitors
01/21/2010WO2010007116A2 New chemical compounds
01/21/2010WO2010007114A2 New chemical compounds
01/21/2010WO2010007100A1 7-substituted amino triazoles as pi3k inhibitors
01/21/2010WO2010007099A1 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
01/21/2010WO2010007027A1 Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
01/21/2010WO2010007000A1 Cancerous disease modifying antibodies
01/21/2010WO2010006982A1 Mimetics of sulfated oligosaccharides
01/21/2010WO2010006755A2 A compound for imaging cell death
01/21/2010WO2010006704A1 Oxazolopyrimidines as edg-1 receptor agonists
01/21/2010WO2010006438A1 Thiosemicarbazone inhibitor compounds and cancer treatment methods
01/21/2010WO2010006432A1 Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
01/21/2010WO2010006377A1 Therapeutic agents
01/21/2010WO2010006376A1 Compositions comprising tea tree oil and methods for the prevention and treatment of cancer
01/21/2010WO2009149279A3 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
01/21/2010WO2009145489A3 Cell-permeable endostatin recombinant protein, a polynucleotide coated with the same, and an anti-cancer preparation containing the same as an active component
01/21/2010WO2009134723A9 Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
01/21/2010WO2009128936A3 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
01/21/2010WO2009124184A3 Azabenzanthrones for the treatment of viral infections, cancer or restenosis
01/21/2010WO2009117706A3 Methods of treatment using anti-mif antibodies
01/21/2010WO2009117116A3 Heat shock protein gp96 vaccination and methods of using same
01/21/2010WO2009115927A3 Nucleotide analogues with quaternary carbon stereogenic centers and methods of use
01/21/2010WO2009103741A3 Use of fsh receptor ligands for diagnosis and therapy of cancer
01/21/2010WO2009067767A3 Targeted radiotherapy
01/21/2010WO2009046841A8 Piperidine and piperazine derivatives for treating tumours
01/21/2010WO2008116064A3 Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
01/21/2010WO2008083107A3 Combinations of antifolate agent and methoxyamine in the treatment of cancer
01/21/2010WO2007041130A3 Deazapurines useful as inhibitors of janus kinases
01/21/2010WO2002078642A9 Differentially-expressed and up-regulated polynucleotides and polypeptides in breast cancer
01/21/2010US20100016938 Diagnosing, monitoring and treating inflammation
01/21/2010US20100016783 Non-invasive systems and methods for in-situ photobiomodulation
01/21/2010US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
01/21/2010US20100016445 Transdermal diethylstilbestrol for treating prostate cancer